Pregled bibliografske jedinice broj: 1225470
Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders
Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders // Medicine, 101 (2022), 30; e29571, 5 doi:10.1097/md.0000000000029571 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1225470 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Incidence of immediate allergic reactions to mRNA
COVID-19 vaccines in adults with drug allergies
and other allergic disorders
Autori
Marković, Ivan ; Božan, Marina ; Perković, Tomislav ; Paušek, Katarina ; Nedeljković, Vanja ; Perković, Marina ; Kelava, Tomislav ; Artuković, Marinko ; Stipić Marković, Asja
Izvornik
Medicine (0025-7974) 101
(2022), 30;
E29571, 5
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
anaphylaxis, COVID-19, drug hypersensitivity, incidence, mRNA vaccines
Sažetak
Concerns have been raised about allergic reactions to messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines. A history of allergic reactions, including anaphylaxis to drugs, has been frequently reported in individuals with anaphylaxis to mRNA vaccines. To estimate the rate of immediate allergic reactions in patients with a history of drug allergy or other allergic disorders. We included adult patients who had received at least 1 dose of an mRNA COVID-19 vaccine at the Special Hospital for Pulmonary Diseases between March 1, 2021, and October 1, 2021, and who reported a history of drug allergy or other allergic diseases (asthma, allergic rhinitis, atopic dermatitis, food or insect venom allergy, mastocytosis, idiopathic anaphylaxis, acute or chronic urticaria, and/or angioedema). Immediate allergic reactions, including anaphylaxis, occurring within 4 hours of vaccination were recorded. Six immediate allergic reactions were noted in the cohort of 1679 patients (0.36%). One patient experienced anaphylaxis (0.06%), which resolved after epinephrine administration, and the other reactions were mild and easily treatable. Most patients with a history of allergies can safely receive an mRNA COVID-19 vaccine, providing adequate observation periods and preparedness to recognize and treat anaphylaxis.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Ivan Marković
(autor)
Asja Stipić Marković
(autor)
Marinko Artuković
(autor)
Marina Perković Kovačević
(autor)
Tomislav Kelava
(autor)
Tomislav Perković
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE